Compare ESPR & BRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESPR | BRSP |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.9M | 736.9M |
| IPO Year | 2013 | 2017 |
| Metric | ESPR | BRSP |
|---|---|---|
| Price | $2.10 | $5.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $7.60 | $6.33 |
| AVG Volume (30 Days) | ★ 5.7M | 911.8K |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 10.79% |
| EPS Growth | 60.71 | ★ 75.24 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $403,135,000.00 | $330,587,000.00 |
| Revenue This Year | $1.53 | N/A |
| Revenue Next Year | N/A | $17.54 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 21.31 | N/A |
| 52 Week Low | $0.73 | $4.37 |
| 52 Week High | $4.18 | $6.17 |
| Indicator | ESPR | BRSP |
|---|---|---|
| Relative Strength Index (RSI) | 32.00 | 64.83 |
| Support Level | $1.02 | $5.46 |
| Resistance Level | $2.99 | $6.00 |
| Average True Range (ATR) | 0.20 | 0.11 |
| MACD | -0.03 | 0.05 |
| Stochastic Oscillator | 6.26 | 96.12 |
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.